The most recent Success stories from EU Research. Select a theme or country from the menus on the left to see more articles
Tick (check) box to add article to PDF "basket"
Using innovative nanotechnologies, an EU-funded project is developing more efficient and sustainable vaccine manufacturing processes. The cost of vaccines puts a brake on wider immunisation, so these new processes will find broad application - especially in developing economies.
Published: 19 February 2018
Viral infections are a major course of disease worldwide. Licensed antiviral drugs are currently only available for a few viruses, such as HIV, influenza and hepatitis C. Through a multi-disciplinary, inter-sectoral training programme, the ANTIVIRALS project is training a new generation of experts to develop novel antiviral drugs
Published: 10 January 2017
Liver disease is one of the leading causes of death in Egypt - second only to cardiac disease - and accounts for almost 10% of overall mortality in the country. To make headway in this area of research, two Egyptian and two EU-based partners joined forces in an EU-funded project that also highlighted the importance of the business side of science.
Published: 20 November 2015
For the first time ever, two ERC grantees, Prof. Luca G. Guidotti and Dr Matteo Iannacone, have observed in vivo how specific white blood cells, so-called cytotoxic T lymphocytes, identify, target and attack liver cells that are infected with the hepatitis B virus. To witness these immune cells in action in real time, the two scientists developed advanced, dynamic imaging techniques. An estimated 240 million people are chronically infected with hepatitis B worldwide.
Published: 28 July 2015
HIV is not curable but it is treatable, states Dr Francesca Incardona, CEO of EuResist Network GEIE and research area manager at Informa s.r.l, the SME responsible for coordinating the EuResist project. The thirty-month initiative was devoted to providing better treatment by implementing an intelligent system that uses patients' clinical information together with viral genetic data.
Published: 12 November 2014
With nearly 200 million infected people worldwide, hepatitis C virus (HCV) represents a significant public health issue. One of the most important challenges is that although the immune system seems to be responsible for much of the disease-associated morbidity, including liver cirrhosis, it is also successful at clearing viral infection for a significant number of patients.
Published: 30 September 2014
Gkikas Magiorkinis, a clinical research fellow from the Department of Zoology at Oxford University in the United Kingdom, has traced history at a microscopic level. By combining epidemiological and molecular data, he has shown how hepatitis C spreads in a population, underlining early diagnosis as a key to preventing the spread of epidemics.
Published: 18 July 2014
EU-funded researchers are identifying and treating patients with Hepatitis B virus (HBV) in West Africa with the aim of reducing their risk of dying from liver cancer. The researchers are also developing a new test to identify those with liver cancer, so treatment can be given sooner saving more lives.
Published: 20 June 2014
Cirrhosis, liver failure and liver cancer are just some of the many life-threatening conditions caused by the Hepatitis C Virus (HCV). Unlike Hepatitis A and B there is no vaccine, and although new treatments for HCV are more effective, they still have harmful side effects.
Published: 23 May 2014
The market for bio-products or bio-based goods has grown sharply over the past few years as consumers embrace foods, fuels, medicines and other products made from renewable biological resources. However, the emerging appetite for bio-products is being held back by bottlenecks in manufacturing, with many processing methods taking far too long and costing too much. A European research project is helping pinpoint the industrial jams, raising hopes that the supply of bio-products can match the soaring demand.
Published: 28 February 2014